Chargement en cours...
The molecular targets of approved treatments for pulmonary arterial hypertension
Until recently, three classes of medical therapy were available for the treatment of pulmonary arterial hypertension (PAH)—prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 (PDE5) inhibitors. With the approval of the soluble guanylate cyclase stimulator riociguat, an addition...
Enregistré dans:
| Publié dans: | Thorax |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BMJ Publishing Group
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4717417/ https://ncbi.nlm.nih.gov/pubmed/26219978 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thoraxjnl-2015-207170 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|